Re­mem­ber that post-mar­ket­ing tri­al? New study con­firms many drug­mak­ers don’t do them — half drag their feet

Ear­li­er this month Sarep­ta con­firmed to us that the post-mar­ket­ing study the FDA re­quired in their con­tro­ver­sial OK for the Duchenne MD drug Ex­ondys 51 — now on the mar­ket at $1 mil­lion a year — was years be­hind sched­ule. 

But it’s right in line with the in­dus­try norm — which runs from slow to glacial.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.